Reduction in heparanase expression as well as prevention of HSPG expression on tumor cells has been shown to reduce tumorgenicity in vivo, highlighting their importance in retaining a malignant phenotype as well as making them attractive targets for therapeutics [114,115,116]. This evidence concerns the gene HSPG2 and neoplasm.